Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands

PURPOSE: Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. METHODS: We studied in 565 patients with type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, Rick I., Hoekstra, Trynke, van den Oever, Niels C. Gritters, Simsek, Suat, van den Bergh, Joop P., Douma, Renée A., Reidinga, Auke C., Moeniralam, Hazra S., Dormans, Tom, Smits, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233181/
https://www.ncbi.nlm.nih.gov/pubmed/34222054
http://dx.doi.org/10.1007/s40200-021-00833-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233181/
https://www.ncbi.nlm.nih.gov/pubmed/34222054
http://dx.doi.org/10.1007/s40200-021-00833-z

Ejemplares similares